Viridian Therapeutics, Inc.DE
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $70.8 | $0.3 | $0.3 | $1.8 | $3.0 |
| Operating income | -$363.4 | -$299.0 | -$254.4 | -$134.3 | -$79.7 |
| Net income | -$342.6 | -$269.9 | -$237.7 | -$129.9 | -$79.4 |
| Cash Flow Statement | |||||
| Free cash flow | -$276.9 | -$232.8 | -$185.1 | -$94.6 | -$54.9 |
Shares outstanding 113.3M · Free float 22.9%
Annual filing data through FY ended December 31, 2025; float as of September 11, 2026.